MX2015001716A - Niclosamida para el tratamiento de tumores solidos. - Google Patents

Niclosamida para el tratamiento de tumores solidos.

Info

Publication number
MX2015001716A
MX2015001716A MX2015001716A MX2015001716A MX2015001716A MX 2015001716 A MX2015001716 A MX 2015001716A MX 2015001716 A MX2015001716 A MX 2015001716A MX 2015001716 A MX2015001716 A MX 2015001716A MX 2015001716 A MX2015001716 A MX 2015001716A
Authority
MX
Mexico
Prior art keywords
niclosamide
treatment
derivatives
solid tumors
combination
Prior art date
Application number
MX2015001716A
Other languages
English (en)
Inventor
Björn Scheffler
Martin Glas
Original Assignee
Life & Brain Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917552&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015001716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Life & Brain Gmbh filed Critical Life & Brain Gmbh
Publication of MX2015001716A publication Critical patent/MX2015001716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invención se refiere a usos terapéuticos novedosos de la niclosamida para el tratamiento del cáncer. En particular, se proporciona una combinación de niclosamida o uno de sus derivados con un agente alquilante para el tratamiento de tumores sólidos. Por otra parte, la niclosamida o uno de sus derivados se pueden utilizar para el tratamiento de tumores sólidos caracterizados por infraexpresión de NFkBIA. Finalmente, la invención se refiere a métodos de diagnóstico para determinar si el tratamiento con niclosamida, solo o en combinación con un agente alquilante, es adecuado para un paciente de cáncer.
MX2015001716A 2012-08-06 2013-08-06 Niclosamida para el tratamiento de tumores solidos. MX2015001716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/065364 WO2014023329A1 (en) 2012-08-06 2012-08-06 Niclosamide and its derivatives for use in the treatment of solid tumors
PCT/EP2013/066484 WO2014023732A1 (en) 2012-08-06 2013-08-06 Niclosamide and its derivatives for use in the treatment of solid tumors

Publications (1)

Publication Number Publication Date
MX2015001716A true MX2015001716A (es) 2015-12-08

Family

ID=48917552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001716A MX2015001716A (es) 2012-08-06 2013-08-06 Niclosamida para el tratamiento de tumores solidos.

Country Status (15)

Country Link
US (1) US9844522B2 (es)
EP (1) EP2879671A1 (es)
JP (1) JP6272861B2 (es)
CN (1) CN104936586A (es)
AU (1) AU2013301542A1 (es)
BR (1) BR112015002706A8 (es)
CA (1) CA2880916A1 (es)
CL (1) CL2015000289A1 (es)
IL (1) IL237125A0 (es)
MX (1) MX2015001716A (es)
PE (1) PE20150764A1 (es)
PH (1) PH12015500252A1 (es)
RU (1) RU2015107753A (es)
SG (1) SG11201500912XA (es)
WO (2) WO2014023329A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313388A4 (en) 2015-06-24 2019-05-15 Duke University CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE
BR112018004069A2 (pt) 2015-09-01 2021-07-13 First Wave Bio, Inc. composição farmacêutica sólida, preparação de enema compreendendo niclosamida, formulação de enema, uso de niclosamida e kit
WO2017048197A1 (en) * 2015-09-16 2017-03-23 Agency For Science, Technology And Research Use of niclosamide in the treatment of p53-deficient cells
JP2019506382A (ja) 2016-01-12 2019-03-07 タイペイ メディカル ユニバーシティ 癌及びウイルスを阻害するための化合物
EP3407848A1 (en) * 2016-01-26 2018-12-05 The Procter and Gamble Company Absorbent cores with high molecular weight superabsorbent immobilizer
CN105687171A (zh) * 2016-01-28 2016-06-22 昆明医科大学 一种阿米诺喹的新用途
TWI631944B (zh) 2016-10-14 2018-08-11 長庚大學 氯硝柳胺及其衍生物的用途
EP3784240B1 (en) * 2018-04-24 2023-09-20 Universidade do Minho Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof for treating wnt6-overexpressing glioblastoma
US20210179615A1 (en) * 2018-07-30 2021-06-17 Duke University Niclosamide analogues and therapeutic use thereof
WO2021142238A1 (en) * 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
WO2022124525A1 (ko) * 2020-12-08 2022-06-16 주식회사 대웅제약 니클로사마이드를 포함하는 근육내 및/또는 피하 투여용 약학적 조성물
CN114601833A (zh) * 2022-04-02 2022-06-10 北京大学口腔医学院 一种***的化学药物组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2002046164A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
JP4452899B2 (ja) * 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
DE60329747D1 (de) 2002-05-02 2009-12-03 Univ Rochester Vektoren mit beiden isoformen von beta-hexosaminidase
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
US8163744B2 (en) * 2005-03-18 2012-04-24 Nexuspharma, Inc. Tetrahydro-isoquinolin-1-ones for the treatment of cancer
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
US20130023498A1 (en) * 2008-02-20 2013-01-24 The Wistar Institute and North Carolina State University MicroRNA Modulators and Method for Identifying and Using the Same
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
JP6228113B2 (ja) * 2011-06-15 2017-11-08 ライフ・アンド・ブレイン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＬＩＦＥ ＡＮＤ ＢＲＡＩＮ ＧｍｂＨ グリア芽腫阻害化合物およびその使用
EP2760473A1 (en) * 2011-09-27 2014-08-06 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas

Also Published As

Publication number Publication date
PH12015500252A1 (en) 2015-03-30
WO2014023329A1 (en) 2014-02-13
IL237125A0 (en) 2015-03-31
WO2014023732A1 (en) 2014-02-13
BR112015002706A2 (pt) 2017-08-08
AU2013301542A1 (en) 2015-02-19
EP2879671A1 (en) 2015-06-10
BR112015002706A8 (pt) 2017-10-10
JP6272861B2 (ja) 2018-01-31
CN104936586A (zh) 2015-09-23
PE20150764A1 (es) 2015-06-04
CL2015000289A1 (es) 2015-06-12
US20150174086A1 (en) 2015-06-25
CA2880916A1 (en) 2014-02-13
RU2015107753A (ru) 2016-09-27
US9844522B2 (en) 2017-12-19
JP2015528437A (ja) 2015-09-28
SG11201500912XA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EP3473651A3 (en) Tumor cell-derived microvesicles
MY158992A (en) Forms of rifaximin and uses thereof
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
GB201004200D0 (en) Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012158780A3 (en) Lung cancer signature
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
IN2012DN06309A (es)
HK1197276A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
HK1209792A1 (en) Use of markers in the diagnosis and treatment of prostate cancer
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2012018866A3 (en) Methods and compositions for the diagnosis and treatment of breast cancer
HK1203190A1 (en) Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER